The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Is Witnessing Impact From Surge In Skin Problems Fueling The Growth Of The Due To Increasing Environmental Exposure And UV Radiation
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Expected To Change From 2026 To 2030?
The market size for pharmaceutical contract development and manufacturing organization (cdmo) for formulations has experienced rapid growth in recent years. It is projected to expand from $54.73 billion in 2025 to $60.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.9%. The growth observed in the historic period can be attributed to the limited availability of specialized peptide api manufacturers, a reliance on in-house peptide production, the expansion of peptide therapeutics pipelines, increasing regulatory compliance requirements, and the adoption of basic chemical synthesis methods.
The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market is poised for significant expansion over the next few years. By 2030, this market is anticipated to reach a valuation of $90.76 billion, exhibiting a compound annual growth rate (CAGR) of 10.6%. The projected growth is attributable to several factors, including advancements in custom peptide synthesis technologies, the expansion of commercial-scale GMP manufacturing, increased outsourcing to CROs and SMEs, the development of lifecycle management and process optimization strategies, and a rising demand for clinical and preclinical peptide API manufacturing. Key trends during this period will involve the increasing outsourcing of peptide API manufacturing to contract manufacturers, a surge in GMP-grade production for both clinical and commercial supply, a heightened need for custom peptide synthesis and purification services, the broadening of peptide therapeutics pipelines across pharmaceutical companies, and a strong focus on process optimization and lifecycle management for peptide APIs.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25876&type=smp
What Factors Are Contributing To The Growth Of The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
The increasing activities in drug development and manufacturing are projected to stimulate the expansion of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market moving forward. These activities encompass pharmaceutical and biopharmaceutical companies intensifying their efforts to research, develop, and produce new drugs. The rise in drug development and manufacturing activities is primarily attributed to the escalating global demand for novel and effective therapeutics, which prompts companies to broaden their development pipelines and accelerate manufacturing timelines. A pharmaceutical CDMO assists drug development by creating and optimizing dosage forms, conducting stability testing, and ensuring regulatory compliance. It also manages the scaling up and production processes, enabling faster and more cost-efficient product launches. For instance, in June 2023, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, the total pharmaceutical production in Europe was $422,803 million (€390,000 million) in 2023, an increase from $393,857 million (€363,300 million) in 2022. Consequently, the expanding drug development and manufacturing activities are fueling the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market.
Which Segment Classifications Are Used In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Segment Analysis?
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market covered in this report is segmented –
1) By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Other Dosage Forms
2) By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology
3) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Users
Subsegments:
1) By Oral Solids: Tablets, Capsules, Granules, Powders, Modified-Release Formulations
2) By Oral Liquids: Syrups, Suspensions, Solutions, Emulsions, Elixirs
3) By Injectables: Vials, Ampoules, Prefilled Syringes, Lyophilized Injections, Injectable Emulsions
4) By Topicals: Creams, Ointments, Gels, Lotions, Foams,
5) By Inhalation Products: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizer Solutions, Nasal Sprays, Inhalation Capsules
6) By Transdermal And Patches: Matrix Patches, Reservoir Patches, Drug-In-Adhesive Patches, Microneedle Patches, Iontophoretic Patches
7) By Other Dosage Forms: Suppositories, Ophthalmic Preparations, Buccal Tablets, Sublingual Tablets, Implants
What Trends Are Shaping The Future Of The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
Leading entities within the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are concentrating on creating sophisticated solutions, including biologic formulation platforms, aimed at improving drug stability and hastening the market introduction of intricate biologic therapies. These platforms represent specialized systems crafted to produce stable and effective formulations for biologic medications. They meticulously adjust components like pH levels, excipients, and delivery mechanisms to boost stability, bioavailability, and overall safety throughout a product’s lifespan. An example of this innovation occurred in June 2025 when WuXi Biologics, a contract research, development, and manufacturing organization headquartered in China, introduced WuXiHigh 2.0, a cutting-edge high-concentration formulation platform. This sophisticated platform facilitates biologic formulations reaching protein concentrations of up to 230 mg/mL, which exceeds the present Food and Drug Administration-approved limit of 200 mg/mL, simultaneously achieving a viscosity reduction of up to 90% via unique excipient mixtures and advanced high-throughput equipment. It tackles significant obstacles in crafting high-concentration biologics, including issues like viscosity and aggregation, and is engineered to enhance injection effectiveness, foster greater patient adherence, and optimize manufacturing results throughout both clinical and commercial phases.
Which Firms Are Contributing To The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Ecosystem?
Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.
Get The Full Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report:
Where Is The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Primarily Concentrated By Region?
Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market 2026, By The Business Research Company
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026
Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
